Search results
Two Philadelphia-area biotech firms report progress on pursuit of a hepatitis B cure - Philadelphia...
The Business Journals· 4 days agoTwo local life sciences companies reported progress this week on their efforts to develop a cure for...
Brii Bio Presents New Data from Its Ongoing Phase 2 Chronic Hepatitis B Trials at EASL™ Congress...
The Tomahawk· 3 days agoNew translational data demonstrate that BRII-179-induced immune responses are associated with high HBsAg reduction in a subset of participants with chronic HBV infection
Vir Biotechnology (NASDAQ:VIR) Trading Down 8%
ETF DAILY NEWS· 22 hours agoVir Biotechnology, Inc. (NASDAQ:VIR – Get Free Report)’s stock price was down 8% during mid-day trading on Friday . The stock traded as low as $11.02 and last traded at $11.02. Approximately ...
... Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure - Arbutus...
Benzinga· 5 days agoAt the end of treatment, 33.3% of patients receiving imdusiran for 48 weeks, interferon (IFN) for 24 weeks and ongoing nucleoside analogue (NA) therapy achieved undetectable levels of HBsAg that were maintained in 100%
...in-human, First-in-class, Phase 1b Immunogenicity Data of VRON-0200, a Novel Checkpoint Modifier...
Benzinga· 5 days agoHighlights from the Data Presentation Initial immunogenicity (n=9) and ongoing safety data (n=13) presented in chronically HBV-infected patients following a single, low dose, prime-only intramuscular injection of
Bulevirtide/Pegylated Interferon Combo Beats Monotherapy for Chronic Hepatitis D
MedPage Today· 4 days agoAt 24 weeks after the end of treatment, HDV RNA levels were undetectable in 46% of patients who...
Gilead Announces New England Journal of Medicine Publication of Data that Demonstrate Bulevirtide...
Morningstar· 4 days agoGilead Announces New England Journal of Medicine Publication of Data that Demonstrate Bulevirtide with PegIFN Achieved Post-Treatment Undetectable HDV RNA - Phase 2b Data Presented at EASL and Published in NEJM Show Potential for Bulevirtide 10 mg
Barinthus Biotherapeutics (NASDAQ:BRNS) Stock Rating Reaffirmed by HC Wainwright
ETF DAILY NEWS· 1 day agoBarinthus Biotherapeutics (NASDAQ:BRNS – Get Free Report)‘s stock had its “buy” rating reiterated by HC Wainwright in a research note issued on Friday, Benzinga reports. They presently have ...
The Hunt for Virus Treatments Continues Post Covid-19
Digital Journal· 3 days agoVancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 7, 2024) - Investorideas.com, a go-to investing platform, releases the second of a two-part series looking at news and ...
The Sustained, Slow Declining, Blood Concentration Profile of NV-387 Enables Infrequent Dosing for...
St. Joseph News-Press· 6 days agoThe Company has found that its lead nanoviricide broad-spectrum antiviral drug candidate NV-387,...
